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Background: When heparin is used as an anticoagulation agent, the risk of bleeding requiring transfusion is increased at both ends of the 
body mass index (BMI) distribution. The present study aimed to examine the relationship of BMI to bleeding risk when bivalirudin is used as the 
anticoagulant agent.
Methods: A cohort of 16,760 patients (pts) who underwent percutaneous coronary intervention (PCI) from 2000 to 2008 was analyzed according 
to the BMI level: <18.5, 18.5-25, 25-30, 30-35, 35-40 and >40 Kg/m2. Bivalirudin was used in 11,433 pts and heparin in 5,338 for PCI. In-hospital 
need for transfusion was systematically collected for each BMI group.
Results: Compared to pts with BMI of 18.5-25, those with BMI 25-40 presented a lower adjusted-risk of transfusion regardless of the anticoagulant 
used. A “U-shaped” relationship between BMI and transfusion was documented for both heparin and bivalirudin. (Figure) Bivalirudin use was 
an independent predictor of a lesser need for transfusion (OR=0.37, 95% CI 0.60-0.89, p=0.002) across all strata of BMI, but the difference in 
individual stratum was significant only for BMI of 18.5-25 after risk adjustment.
Conclusion: The risk of PCI-related bleeding has a similar relationship to BMI in pts treated with bivalirudin to those receiving 
heparin, but bivalirudin reduces the risk of peri-PCI bleeding and appears to have a beneficial effect across all strata of BMI.
